Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study

PURPOSE: Migraine can negatively impact patient functioning and quality of life. Here, we report the effects of galcanezumab (GMB), a humanized monoclonal antibody that binds to calcitonin gene-related peptide, on patient-reported outcome (PRO) measures in migraine. METHODS: CGAJ was a Phase III, ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ford, Janet H., Stauffer, Virginia L., McAllister, Peter, Akkala, Sreelatha, Sexson, Matthew, Ayer, David W., Wang, Shufang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886775/
https://www.ncbi.nlm.nih.gov/pubmed/32944843
http://dx.doi.org/10.1007/s11136-020-02632-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886775/
https://www.ncbi.nlm.nih.gov/pubmed/32944843
http://dx.doi.org/10.1007/s11136-020-02632-0

Ejemplares similares